Journal
JOURNAL OF NEUROLOGY
Volume 255, Issue 10, Pages 1449-1463Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00415-008-0061-1
Keywords
Multiple Sclerosis; immunotherapy; randomized trials; monoclonal antibodies; interferon beta; glatirameracetate; treatment escalation
Categories
Ask authors/readers for more resources
This review updates and extends earlier Consensus Reports related to current basic and escalating immunomodulatory treatments in multiple sclerosis (MS). The recent literature has been extracted for new evidence from randomized controlled trials, open treatment studies and reported expert opinion, both in original articles and reviews, and evaluates indications and safety issues based on published data. After data extraction from published full length publications and critically weighing the evidence and potential impact of the data, the review has been drafted and circulated within the National MS Societies and the European MS Platform to reach consensus within a very large group of European experts, combining evidence-based criteria and expert opinion where evidence is still incomplete. The review also outlines a few areas of controversy and delineates the need for future research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available